Orchestra BioMed Holdings, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureOct 1 →Insiders3 insiders bought $221,331 in 7 open-market buys. 3 insiders sold $58,182, 1 of 2 sales on a 10b5-1 plan.→HoldersRTW Investments 15.9%Perceptive 8.4%BlackRock 4.2%→PeersClosest companies: EWTX, GUTS, TNYA→
From the filings
Figures
- Revenue
- $32.0Mlast 12 months
- Net income
- −$59.0Mlast 12 months
- Operating cash flow
- −$54.5Mlast 12 months
- Cash and equivalents
- $20.5Mat the last balance sheet
- Total debt
- $15.0Mat the last balance sheet
- Shares outstanding
- 60.1M shareson issue